Skip to main content

Table 1 Rates of complete remission in dogs with CTCL

From: Is CCNU (lomustine) valuable for treatment of cutaneous epitheliotropic lymphoma in dogs? A critically appraised topic

  CCNU Pegylated liposomal doxorubicin VDC-1101 and prednisone Masitinib
References N CR (N, %) N CR (N, %) N CR (N, %) N CR (N, %)
Morges, 2014 [4]      10 0 (0%)   
Risbon, 2006 [2] 46a 15 (33%)       
Williams, 2006 [3] 36 6b (33%)       
Graham, 1999 [6] 5 5c (100%)       
Vail, 1997 [5]    9 3 (33%)     
Holtermann, 2016 [7]        10d 2 (20%)
TOTAL 87 26 (30%) 9 3 (33%) 10 0 (0%) 1- 2 (20%)
  1. Abbreviations: CR complete remission, N number of dogs
  2. a14 dogs received CCNU monotherapy, 27 also received glucocorticoids that were later either tapered, discontinued or maintained. The co-administration of prednisone was reported not to be significantly associated with the response or its duration. Other concurrent medications included PEG L-asparaginase (6 dogs), essential fatty acids (8), nonsteroidal anti-inflammatory drugs (3), retinoids (2), and interferon (1)
  3. b67% of the dogs experiencing a CR also received concurrent glucocorticoids
  4. c2 dogs may have received concurrent surgery
  5. dthe response was assessed on the three most dominant “target” lesions